RE:RE:RE:RE:RE:RE:RE:RE:Unfortunately the market perceives phase one as a failure Yaz, from Nov 8. Nr.. "No sign of progression of the desease", at 180 day result. Read below.
Discussion:
Patients one and two have a previous history of Upper Urinary Tract Urothelial Carcinoma (“UUTUC”) diagnosed prior to their PDT treatment, while patients 3 and 4 are at high risk of UUTUC. This clinical observation, along with peer-reviewed clinical research1,2 raises the possibility that the source of patient one, two and three’s recurrent NMIBC may have originated by seeding in the bladder from these extravesical sites, potentially confounding the exploratory outcomes for these patients (In this NMIBC patient population, 80% of patients recur, while 50% of patients progress). The extravesical upper tract locations of all treated patients were not exposed to the PDT treatment in the Study.
Although patient one, two and three, treated at the MRSD (1/2 of Therapeutic Dose), recurred at 180 days post treatment; there was no sign of progression of the disease; indicating, that they may benefit from multiple PDT treatments, delivered between 90 to 180 days post treatment.
The interim data obtained to date suggests that the Theralase PDT treatment was able to achieve the primary, secondary and exploratory objectives of the Study at both the MRSD and Therapeutic Dose, delaying recurrence and more importantly delaying progression of NMIBC, for more than 90 days post PDT treatment, which would be of particular benefit for NMIBC patients; especially, patients who do not have a previous history of UUTUC.
Read more at https://www.stockhouse.com/news/press-releases/2017/11/08/theralase-provides-interim-data-analysis-on-anti-cancer-treatment-for-first#Id4HSRlvIz4URHzc.99 bionicjoe wrote: Damn , people, has another pharma treated a patient once, and a 1000% of the patients had their progression stopped for over 180 days??? Any one pharma do that? Only one, TLT!!!!
Easy macman1519, the sampling was only 3 patients and you're wrong. The company made a flat out statement that progression was stopped between 90 & 180 days not for over 180 days as you deviously insinuate. Not only did they not elaborate which would have given us more insight but the timeframe leaves it open to a patient's visible cancer beginning the process of taking hold again in as little as 100 days after receiving the treatment. Nobody knows. Whether it's 90 days or 179 days it is little comfort for cancer patients when they are praying for a treatment that will for years keep their cancer from coming back. We need to recognize that's how the market appraises the progression figures.
Not to be rude but many posting here including those who profess to have medical training, are not dealing with reality. They continually quote snippets of data out of context from the Nov 8th company PR to support their contention that with the early data TLT has already made great strides in treating NMIBC. Even a novice investor will ask the question if that's the case then where is the recognition from the cancer community hailing TLT's scientific achievements? Closer to home, why if the results to date are so outstanding and revolutionary isn't HC doing its part and Fast Tracking the treatment? No matter how hard the market looks it can't find any support that TLT's PDT treatment has made a major step in the fight against cancer.
Let's face it the results to date are nowhere near what shareholders expected before the trial began. With so little genuine and undisputed scientific evidence so far I think the sp is fairly valued.